Trial reportSpine2026
Cost-Effectiveness of ABM/P-15 Versus Allograft in Degenerative Spondylolisthesis Surgery : Ten-Year Follow-Up on a Randomized Controlled Trial.
Trial report in Spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designRandomized controlled trial.
objectiveThe aim of this study was to investigate whether ABM/P-15 was cost-effective compared with allograft as a bone graft extender for uninstrumented posterolateral fusion for degenerative spondylolisthesis with spinal stenosis in elderly patients. SUMMARY OF BACKGROUND DATA: In an increasingly elderly population with higher expectations of good health and quality of life, the need for durable surgery with minor risks of implant-related reoperations is growing. Specifically for lumbar fusion surgery, the need for a reliable bone graft material with acceptable fusion rates and low graft-related morbidity and risk of reoperation is important.
methodsThis cost-effectiveness analysis was based on a single-center, blinded, randomized controlled trial, where patients with symptomatic degenerative spondylolisthesis were randomly assigned 1:1 to either ABM/P-15 or Allograft as bone graft material in uninstrumented posterolateral fusion. Quality-adjusted life years (QALY) were obtained from EQ-5D-3L. Use of health services was obtained from patient charts, costed and accumulated up to 10 years after index surgery.
resultsThe study included 101 patients with no inter-group differences in preoperative characteristics. On the basis of a bootstrapped analysis, the estimated the mean QALY gain for the ABM/P-15 group was 0.42 points (95% CI [-0.17; 1.08], P =0.185) greater compared with the Allograft group. Compared with the Allograft group, patients in the ABM/P-15 group had 20% less costs due to a significantly lower reoperation rate (18% vs. 43%, P =0.024), fewer visits to the outpatient clinic, magnetic resonance images, and fewer days of hospitalization.
conclusionsThe choice of bone graft material significantly affected cost-effectiveness of posterolateral lumbar fusion in elderly patients with degenerative spondylolisthesis at 10-year follow-up. ABM/P-15 showed dominance over Allograft with improved outcomes, lower health care costs, and lower reoperation rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.